story of the week
Baricitinib vs Dexamethasone for Adults Hospitalised With COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Respiratory Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial
Lancet Respir Med 2022 May 23;[EPub Ahead of Print], CR Wolfe, KM Tomashek, TF Patterson, CA Gomez, VC Marconi, MK Jain, OO Yang, CI Paules, GMR Palacios, R Grossberg, MS Harkins, RA Mularski, N Erdmann, U Sandkovsky, E Almasri, JR Pineda, AW Dretler, DL de Castilla, AR Branche, PK Park, AK Mehta, WR Short, SLF McLellan, S Kline, NM Iovine, HM El Sahly, SB Doernberg, MD Oh, N Huprikar, E Hohmann, CF Kelley, M Holodniy, ES Kim, DA Sweeney, RW Finberg, KA Grimes, RC Maves, ER Ko, JJ Engemann, BS Taylor, PO Ponce, L Larson, DP Melendez, AM Seibert, NG Rouphael, J Strebe, JL Clark, KG Julian, AP de Leon, A Cardoso, S de Bono, RL Atmar, A Ganesan, JL Ferreira, M Green, M Makowski, T Bonnett, T Beresnev, V Ghazaryan, W Dempsey, SU Nayak, LE Dodd, JH Beigel, AC KalilFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.